• A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

  NCT04747431

  Active, not recruitingInterventionalPhase 1Phase 2Updated May 15, 2026
• Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

  NCT04408625

  Active, not recruitingInterventionalPhase 1Phase 2Updated Jul 16, 2026
• A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

  NCT03636204

  CompletedInterventionalPhase 1Updated Jul 27, 2020
• A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

  NCT05040217

  Active, not recruitingInterventionalPhase 1Updated Jul 10, 2026
• Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

  NCT02149160

  Unknown statusInterventionalPhase 2Updated Mar 23, 2016
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

  NCT04374136

  TerminatedInterventionalPhase 3Updated Jan 21, 2026

ClinicalTrials.gov ID

NCT06064890

Lead Sponsor

AviadoBio LtdINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

18Estimated

Last Update Posted

Aug 13, 2026Actual

Start Date

Aug 30, 2023Actual

Primary Completion Date

Apr 1, 2027Estimated

Completion Date

Mar 21, 2030Estimated

Official Title

A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Brief Summary

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function.

The main questions that the study aims to answer are:

1. Is a one-time treatment with AVB-101 safe for patients with FTD-GRN?
2. Does a one-time treatment with AVB-101 restore PGRN levels to at least normal levels?
3. Could AVB-101 work as a treatment to slow down or stop progression of FTD-GRN?

In this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.

• Frontotemporal Dementia
• FTD
• FTD-GRN
• Dementia, Frontotemporal

• Intrathalamic AAV.PGRN administration
• Intrathalamic AVB-101

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Male or female, 30 to 75 years of age
• Carriers of a pathogenic GRN mutation
• FTD as evidenced by CDR + NACC FTLD global score of 0.5, 1.0, or 2.0
• Presence of 1 or more of the criteria for diagnosis of possible bvFTD or PPA
• Able and willing to comply with all procedures and the study visit schedule
• Able and willing to give written informed consent prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they lose capacity to consent at some point during the study OR If, in the Investigator's opinion, the subject lacks capacity to consent, written informed consent of their legal representative must be obtained in accordance with local laws, regulations, and/or customs. In countries where local laws, regulations, and/or customs do not permit subjects who lack capacity to consent to participate in this study, these subjects will not be enrolled
• An identified, informed study partner who is able and willing to support the participant in the study and to provide assessments of the participant during the study

Exclusion Criteria:

• Severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and/or pose unacceptable safety risk to the subject
• Any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency
• Clinically significant abnormality on MRI at Screening considered to be a contraindication to Intrathalamic infusion
• Surgically significant pattern of brain atrophy on MRI at Screening that interferes with planned neurosurgical trajectory
• Previous treatment with any gene or cell therapy
• Previous treatment with any investigational medicinal product (IMP) within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment
• Concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the participant or interfere with study conduct or the participant's ability to comply with study procedures including neurosurgical administration under anesthesia

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

AviadoBio LtdINDUSTRY

diptiwagle@uzleuven.be+32 16 34 60 39